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Abstract  
The purpose of the study was to investigate the effect of inhaling 
1600 µg of salbutamol (SAL) on 30 m sprint before and after the 
Yo-Yo Intermittent Recovery test. In a randomised cross over 
single blind study 13 male non-asthmatic, football players 
volunteered (mean ± SD; age 18.1 ± 0.9 years; weight 69.5 ± 8.3 
kg; height 1.78 ± 0.07 m). Participants completed two visits and 
were randomly assigned to either (SAL) or (PLA) treatment and 
performed a set of three sprints of 30 m before and after the Yo-
Yo Intermittent Recovery Test (Yo-Yo IRT). Best sprint and 
mean sprint were analysed in addition to the distance covered 
during the Yo-Yo IRT; rating of perceived exertion and heart rate 
were collected at the end of each level completed. Repeated 
measures ANOVA were performed to investigate changes in 
performance between groups. Following the inhalation of supra-
therapeutic salbutamol dose (1600 µg) neither 30 m sprint time 
(PLA 4.43 ± 0.14 s; SAL 4.44 ± 0.15 s, p = 0.76) nor distance 
covered in the Yo-Yo IRT test reported significant variation 
between PLA conditions (1660 ± 217 m) and SAL (1610 ± 229 
m, p = 0.16). Moreover, lactate values, heart rate and RPE did not 
differ significantly between groups. The inhalation of 1600 µg 
salbutamol does not enhance 30 m sprint performance in non-
fatigued and fatigue conditions. Our findings suggest when 
football players acutely inhale double the permitted dose of 
salbutamol, as indicated in the World Anti-Doping Agency List 
of Prohibited Substances and Methods, they will not experience 
improvements in sprint or endurance performance.    
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Introduction 
 
Athletes with asthma related conditions are permitted to 
use inhaled salbutamol in accordance with current WADA 
regulations (WADA, 2019). Although a therapeutic dose 
of inhaled salbutamol ranges from 200-400 µg, football 
players are permitted to inhale up to 800 µg in any 12 hours 
period and 1600 µg in a 24 hours period. Limited data is 
available to explain whether football players may gain an 
ergogenic advantage from doses of inhaled salbutamol up 
to 1600 µg. 
Recent research by Dickinson et al. (2015) suggests 
that doses of up to 1600 µg of inhaled salbutamol do not 
improve repeated sprint performance following a 52 
minute football specific treadmill running protocol. 
However, others have observed improvements in sprint 
cycling after the inhalation of salbutamol 180 µg (Signorile 
et al., 1992) and 15 mg Terbutaline (Kalsen et al., 2016). 
The latter authors suggested the 8% improvement in power 
output over a 10 s sprint cycling performance was 
associated with a greater fatigue resistance in type II fibers 
due to increased rates of glycogenolysis and glycolysis. 
Furthermore, when well trained swimmers inhale a 
combination of salbutamol (1600 µg), formoterol (36 μg) 
and salmeterol (200 µg), their 100 m sprint performance is 
enhanced by 1 s (Kalsen et al., 2013). Recently, Hostrup et 
al. (2016) demonstrated that initial Wingate sprint 
performance was enhanced after 8 mg oral salbutamol 
administration but subsequent sprints were not enhanced in 
the same way.  
Acute use of short acting β2-agonists may result in 
ergogenic action leading to improvements in peak power 
and one-off sprint performance. However, limited data 
suggest repeated sprint performance, with and without pre 
fatigue, is not enhanced. The purpose of this study is to 
investigate the potential ergogenic action of inhaled 1600 
µg salbutamol on 30 m sprint performance in football 
players before and after the Yo-Yo intermittent recovery 
test (Yo-Yo IRT). 
 
Methods 
 
Participants 
Thirteen male football players volunteered and provided 
written and verbal informed consent. All players took part 
in amateur football league, competing once a week and 
trained specifically for football at least three times a week. 
All participants were free from respiratory disease 
including asthma related conditions, cardiopulmonary 
disease, metabolic disease and musculoskeletal injury 
(Table 1). 
 
Table 1. Descriptive features of participants (n = 13) 
expressed as mean and standard deviation (Mean ± SD) 
Parameters              
Age (years)                       18.1 ± 0.9 
Height (m)                     1.78 ± 0.07
Weight (kg)                       69.5 ± 8.3
BMI (kgꞏm-2)                    22 ± 1.7
VO2Max (mL/min/kg)      51.2 ± 3.4
HRMax  (bpm)                            198 ± 4.0
Training (h/week 8 ± 1.4
RPEMax  (u.a.)                      9 ± 1.0
BMI, body mass index; VO2Max, maximal oxygen uptake 
 
The participants completed all assessments at the 
same time of the day (within 1 h), separated by a minimum 
of 48 hours. They were instructed to sleep for at least 7 
hours, drink at least 35 mL/kg/day of water, refrain from 
consumption of alcohol for 24 hours prior to the visit and 
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avoid vigorous exercise on the day before each of the 
following visits.  
Ethical approval (no. 521415) for this study was 
provided by the University of Kent, Faculty of Science, 
Local Research Ethics Committee.  
 
Experimental protocol 
Participants visited the respective testing facilities on three 
separate occasions, the first of which was a familiarization 
session. The final two visits were completed in a single 
blind random order and separated by two days. On each of 
these separate occasions players were required to complete 
three maximal 30 m sprints followed by the Yo-Yo IRT 
and followed by a further three maximal 30 m sprints, 
performed 5 minutes after the cessation of the Yo-Yo IRT 
(Figure 1). 
Fifteen minutes prior to the initiation of the first 
three 30 m sprints players inhaled one of the following 
treatments, via a pocket chamber:  
Treatment 1: 16 inhalations of placebo containing 
water vapour (PLA). 
Treatment 2: 16 inhalations of 100µg salbutamol 
(SAL; Ventolin Evohaler- GlaxoSmithKline, UK).  
The order of PLA and SAL was randomized and 
counterbalanced by an order generated by online software 
(randomization.com).  
 
Motivation and Mood questionnaires 
Before each visit participants completed questionnaires to 
measure motivation to train and mood via the Brunel Mood 
Scale and Matthews questionnaire (Matthews et al., 2001; 
Terry et al., 2003). The Brunel Mood Scale (BRUMS) was 
used to quantify current mood at baseline, before the 30 m 
sprint (pre-sprint) and post-sprint. The questionnaire 
included 24 items (e.g. “angry, uncertain, miserable, tired, 
nervous, and energetic”) divided into six subscales: anger, 
confusion, depression, fatigue, tension, and vigour. Each 
item was answered on a five point scale (0 = not at all, 1 = 
a little, 2 = moderately, 3 = quite a bit, 4 = extremely), and 
each subscales, with the respective relevant items, was 
calculated with a raw score in the range of 0–16. For this 
experiment, only scores for the fatigue and vigour 
subscales were considered as subjective ratings of fatigue. 
Motivation. Motivation related to Sprint and Yo-Yo 
test was measured using the success motivation and 
intrinsic motivation scales (Matthews et al., 2001). Each 
scale consisted of 7 items scored from 0 to 4 points (0 = not 
at all, 1 = a little bit, 2 = somewhat, 3 = very much, 4 = 
extremely). Motivation questionnaire was administered 
immediately before the 30 m sprint test. 
 
Sprint test 
Before the assessments all participants completed the 11+ 
warm-up (Bizzini and Dvorak, 2015) concluding with 
standardised mobility and flexibility exercises. After the 
warm up football players completed three 30 m maximal 
sprints with 60 s passive recovery time between each sprint 
(Taskin, 2008). Five minutes following the end of the Yo-
Yo IRT, participants completed a further three 30 m sprints  
with a 60 s active recovery between each one.  
Consistent verbal encouragement was given to the 
players during each sprint. Players were encouraged to 
complete the sprints as fast as they could.  In order to record 
the time to cover the distance, a system of light gates 
(Brower Timing, Fairlee, Vermont, USA) were utilised. 
Heart rate (HR) was recorded throughout the sprints using 
heart rate monitor and watch (Polar m400 HR, Polar Oy 
Finland); peak HR was recorded for each condition. The 
mean time of the three efforts and the best sprint time were 
recorded. At the end of each set of three sprints, a drop of 
blood (0.5 μL) was collected from the ear to obtain a 
capillary blood lactate sample (Lactate Pro, Arkray KDK, 
Japan). 
 
Yo-Yo test (Yo-Yo IRT) 
The Yo-Yo IRT test consisted of repeated 2 x 20 m shuttle 
runs at a progressively increasing speed controlled by      
audio bleeps (Krustrup et al., 2003). Between each running 
bout the players had a 10 s active rest period, in a space of 
5 m where they are encouraged to walk or jog. Following 
the completion of each stage players were asked to provide 
a rating of perceived exertion on a scale between 6 and 20 
(Borg, 1982). When the players failed on two occasions to 
complete the 2 x 20 m within the required time the test was 
concluded and the distance covered was recorded. Heart 
rate was recorded during the entire fitness trial.  
 
Statistical analysis 
All data are presented as mean ± SD unless otherwise 
stated. Assumptions of statistical tests for normal 
distribution and sphericity of data were checked as 
appropriate and Greenhouse-Geisser correction to the 
degrees of freedom was applied when violations to 
sphericity were found. Repeated measures ANOVAs were 
used to determine the effect of time (Sprint Pre vs Sprint 
Post) and condition (SAL vs. PLA) on peak power, mean 
power and highest speed reached during 30-m sprint. This 
same analysis was adopted to investigate vigor (pre-
treatment vs. post-treatment), motivation (pre-treatment) 
and each physiological and perceptual parameter (Heart 
rate, Blood Lactate and RPE) at iso-time [end of warm-up 
(0 min) and each Yo-Yo IRT level completed]. 
Heart rate and RPE during the Yo-Yo IRT were 
analyzed from the start of the test (level 5) up to the end of 
level 16; beyond this point only the highest value was 
recorded and considered their maximum, as football 
players began to drop out of the test from level 16 onwards. 
Significance was set at p < 0.05 (2-tailed) for all analyses 
and effect sizes for the repeated measures ANOVAs were 
calculated as partial eta squared (η²p), using the small = 
0.02, medium = 0.13 and large = 0.26 interpretation for 
effect size. All data analysis was conducted using the 
statistical packages for social science (SPSS, version 21, 
IBM, U.S.).  
 
Results 
 
All thirteen-football players completed the Yo-Yo IRT test 
and the sprint assessment in both conditions, PLA and 
SAL. None of the participants reported unpleasant        
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symptoms such as tachycardia, nausea, headache or sleep 
disturbance after inhaling 1600 µg salbutamol; none of the 
participants   could   correctly   distinguish the difference 
between the PLA and SAL conditions. 
 
30 m Sprint Pre and Post Yo-Yo IRT  
30 m sprints conducted pre and post Yo-Yo IRT demon-
strated no difference between PLA and SAL conditions for 
mean sprint time (p = 0.152, η²p = 0.163), best sprint time 
(p = 0.753 η²p = 0.008); highest speed reached (p = 0.859, 
η²p = 0.003; Figure 1). 
 
 
 
 
 
 
 
  
 
 
 
Figure 1. Best Sprint (A), Mean Sprint (B), Maximal speed 
(C) at pre and post Yo-Yo IRT. Data are presented by Mean and 
SD.  
 
Blood lactate following the pre Yo-Yo IRT 20 m 
sprints was not different between SAL and PLA (p = 0.450, 
η²p = 0.021). The post Yo-Yo IRT 30 m sprint lactate val-
ues were not different between SAL and PLA conditions 
(p = 0.882, η²p = 0.007; Figure 2). 
HR was not different between PLA and SAL (p = 
0.123) during the sprint pre and post Yo-Yo IRT.  
 
Yo-Yo Intermittent Recovery Test 
The distance covered during the Yo-Yo IRT did not differ 
between PLA and SAL (p = 0.153, η²p = 0.224; Figure 3). 
No significant changes were observed between PLA and 
SAL during the Yo-Yo IRT for HR (p = 0.102, η²p = 0.095) 
or RPE (p = 0.195, η²p = 0.134). HR was not different be-
tween PLA and SAL at any level of the Yo-Yo IRT (Figure 
4). RPE was not different between PLA and SAL at any 
level of the Yo-Yo IRT (Figure 4). 
 
 
 
 
 
Figure 2. Lactate values collected after sprint pre Yo-Yo IRT 
and after sprint post Yo-Yo IRT. Data are presented by Mean and 
SD. 
 
 
 
 
 
Figure 3. Distance covered by SAL and PLA during the Yo-
Yo IRT. Data are presented by Mean and SD. 
 
 
 
 
 
 
Figure 4. Heart rate and RPE response at the end of each Yo-
Yo IRT level completed by the participants. Data are presented 
by Mean and SD. Level 10 in heart rate graph is missing because not all 
participants were able to complete it. 
 
Mood and Motivation questionnaire 
The mood questionnaire revealed a significant decrease in 
vigor over time in both conditions (p = 0.01) with no main 
effect of condition (p = 0.49, η²p =0.01) or condition × time 
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interaction (p = 0.29, η²p =0.17; Table 2). No differences 
were found for intrinsic motivation (p = 0.62, η²p =0.09) 
and motivation to succeed the task (p = 0.78, η²p =0.02; 
Table 2)  
 
Table 2. Vigor at pre and post test and Motivation at pre test 
in SAL1600 and PLA conditions (Mean ± SD). 
SAL PLA 
Pre Post Pre Post 
BRUMS vigour (A.U.) 5.4 ± .3 3.3 ± .5* 5.7 ± .6 3.6 ± .4*
Motivation  (A.U.) 5.3 ± .5  5.1 ± .4  
A.U. = arbitrary units; SAL = salbutamol; PLA = placebo. * p < 0.01; 
 
Discussion 
 
Our study suggests that non-asthmatic football players who 
inhale 1600 µg of salbutamol do not experience improve-
ments in 30 m sprint performance pre or post the Yo-Yo 
IRT test. Furthermore, Yo-Yo IRT performance, HR, 
blood lactate or RPE are not altered as a result of prior in-
halation of 1600 µg of salbutamol. 
Our results are similar to previous findings from our 
research group (Dickinson et al., 2015), where we did not 
observe any significant change in repeated sprints follow-
ing a running protocol that simulated one half of a football 
match. The absence of ergogenic action on 30 m sprint per-
formance found in this study could be a summation of fac-
tors including the type of drug and the dosage used in our 
studies compared to other studies. While acute doses of in-
haled salbutamol up to 1600 µg does not seem to enhance 
30 m sprint, 15 mg of inhaled terbutaline does increases 30 
s cycling sprint peak and mean power by 3% in recreational 
athletes (Hostrup et al., 2014). High doses of inhaled ter-
butaline (15 mg) have also been shown to improve 10 s cy-
cling sprint performance in moderately trained cyclists, 
with mean (8.3% ± 1.1%) and peak (7.8% ± 2.5%) power 
greater with terbutaline than with placebo (Kalsen et al., 
2016). The improvements seen in other studies with regard 
to sprint and power performance could be due to greater 
potentiation of adrenergic receptors at very high dosages 
(Baker, 2010) and by the ability to induce a response at a 
given receptor induced by the drug administered. In regard 
to this, inhaled terbutaline may lead to same systemic con-
centration of doses administered orally with less side ef-
fects and similar plasma and urine half-life (Elers et al., 
2012b).  
Blood lactate is an indirect marker of muscle gly-
colysis; in our study we did not find a difference in blood 
lactate between PLA and SAL conditions. It has previously 
been reported that an 800µg dose of inhaled salbutamol can 
lead to detectable systemic concentrations of 10.95 ng/mL 
in healthy subjects (Elers et al. 2012a; 2012b). In our study 
we were not able to directly measure the concentration of 
salbutamol in the blood or in urine. We can therefore not 
assume that a dose of 1600 µg inhaled salbutamol, 15 
minutes prior to the initial 30 m sprints, was a sufficient to 
result in significant systemic circulation. Future studies 
may benefit from indirectly monitoring systemic circula-
tion of salbutamol by analysing ATP and phosphocreatine 
(PCr) to better understand the action of short acting β2-ag-
onists on skeletal muscle cell beta-2 receptors. Previously, 
short acting β2-agonists has been shown to improve rates 
of glycolysis and glycogenolysis in the sarcoplasmic retic-
ulum, improving 10 s sprint cycling performance (Kalsen 
et al., 2016). Low levels of circulating salbutamol may also 
explain why we had no reports of significant side effects 
from any of our participants. 
Another way we could have estimated systemic cir-
culation of salbutamol would be to measure urine concen-
tration. In addition, performing this analyses would have 
also allowed us to investigate the potential for football 
players, who inhale double the permitted salbutamol, to be 
at risk of providing a urine sample during a doping test that 
exceeds the WADA 1000 ngꞏml-1 threshold for an adverse 
analytical finding (WADA, 2019). Previous findings 
(Dickinson et al., 2014; 2015) suggest the acute inhalation 
of supra-maximal doses of salbutamol (up to 1600 µg) 
along-side acute loss of body mass of up to 5% can lead to 
individuals presenting with a urinary salbutamol concen-
tration above 1200 ngꞏml-1. Haase et al. (2016) confirmed 
that dehydration can significantly affect the concentration 
of salbutamol in urine samples. Based upon Dickinson et 
al, (2015) and Haase et al. (2016) results, WADA now has 
adjusted its methods to analyse the concentration of salbut-
amol with dehydration state of the athletes (WADA, 2019). 
In our study, we did not observe any improvement 
in Yo-Yo IRT performance. This finding is similar to that 
of previous investigations that have demonstrated inhaled 
salbutamol does not improve endurance performance or 
VO2 peak (Elers et al., 2012). The available data from pre-
vious investigations has been analysed in a meta-analysis 
(Pluim et al., 2011), in which the authors concluded that 
endurance performance was not influenced by supra-ther-
apeutic doses of inhaled salbutamol (up to 800 µg). Fur-
thermore, a study by Elers et al. (2012) reported that inhal-
ing acute supra-therapeutic doses (8mg) of salbutamol did 
not improve peak VO2 or oxygen kinetics. 
The endurance component of football may be com-
promised if players inhale large doses of β2-agonists on a 
daily basis. When trained male participants inhaled ter-
butaline (4 mg) and completed high intensity interval train-
ing, over a four week period, they found that exercise per-
formance and oxidative capacity improvements were atten-
uated when compared against a placebo group (Hostrup et 
al., 2018). Therefore, footballers frequently using high 
doses of inhaled β2-agonists may find the expected en-
hancements in endurance performance from their high in-
tensity interval training are blunted.   
In our study, we advised participants how to use the 
inhaler and observed them using the inhaler but we did not 
train them. Future studies may also benefit from thor-
oughly training inhaler technique with their participants to 
improve the delivery of salbutamol into the lower airways.  
 
Conclusion 
 
This study demonstrates inhalation of 1600 µg salbutamol  
does not improve 30 m sprint performance in trained ama-
teur football players. Furthermore, our findings suggest 
that acute inhalation of 1600 µg salbutamol will not lead to 
improvements  in  Yo-Yo  IRT  performance  in   football 
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players.  Although 1600 µg of inhaled salbutamol is double 
the current permitted dose (800 µg) by WADA regulations 
(WADA, 2019), our study suggests footballers using in-
haled salbutamol for asthma therapy within the doses per-
mitted WADA regulations will not experience an ergo-
genic action in either their sprint or endurance perfor-
mance.  
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Key points 
 
 Investigate the potential ergogenic action of inhaled 
1600 µg salbutamol on 30 m sprint performance.   
 Investigate the potential ergogenic action of inhaled 
1600 µg salbutamol on 30 m sprint performance after 
fatigue protocol. 
 Investigate the potential ergogenic action of inhaled 
1600 µg salbutamol before and after a Yo-Yo inter-
mittent recovery test. 
   Investigate the effects of inhaled short-acting beta-2 
agonist administration on both aerobic and anaerobic 
exercise replicating intermittent sports performance. 
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